ADPT

SEC source: 0001780664-26-000039 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 272,848

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000039 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 284,729

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 380,502

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000039 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,610

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000037 · form4.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 308,491

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.23 to $26.09, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000037 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 320,372

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.95 to $26.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000037 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 332,253

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.34 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 378,301

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $30.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,202

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.89 to $28.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 380,302

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.89 to $27.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001820885-26-000025 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,350

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

SEC source: 0001780664-26-000035 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 344,134

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 382,984

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000035 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,015

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000035 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 367,896

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377,802

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $28.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 383,602

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 389,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780660-26-000024 · form4.xml · derivative · entry 9

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,765

Underlying: Common Stock · 9,377 shares

Expires 2035-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000024 · form4.xml · derivative · entry 8

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,259

Underlying: Common Stock · 9,377 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000024 · form4.xml · derivative · entry 7

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,075

Underlying: Common Stock · 8,038 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,867

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,565

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 247,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000024 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 228,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001820885-26-000023 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 395,794

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

SEC source: 0001852578-26-000007 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,100

F1 · price: Price is not applicable to dispositions resulting from bona fide gifts.

SEC source: 0001852578-26-000005 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,639

SEC source: 0001780649-26-000014 · form4.xml · derivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 278,676 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was fully vested and exercisable and would have expired on February 7, 2028.

SEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180,518

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180,722

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,459,194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001274139-26-000004 · form4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was fully vested and exercisable and would have expired on October 18, 2026.